Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our recommendation for VRTX stock.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same time, ...

RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

This is the first Huawei phone that doesn't run Android Open Source Project (AOSP), which is what Huawei had been using since it was banned by the US. Instead, the phone runs HarmonyOS Next, which ...

FormFactor (FORM) is a $2.5 billion OEM of automated wafer probe cards and other testing devices used in the back-end portion of the semiconductor manufacturing process. FORM serves the ...

In the latest development, Google today announced that it would be adding Chirp 3 — its speech-to-text and HD text-to-speech models — to its Vertex AI development platform starting next week.

and optimised applications tailored for the new form factor. While pricing details remain under wraps, Yu has hinted that it will be an accessible product for the masses. As the official launch ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

It has been about a month since the last earnings report for FormFactor (FORM). Shares have lost about 16.9% in that time frame, underperforming the S&P 500. Will the recent negative trend ...